Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Medical | 5 | 2023 | 1930 | 1.250 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2024 | 38 | 0.910 |
Why?
|
| Thiadiazoles | 1 | 2024 | 64 | 0.900 |
Why?
|
| Viloxazine | 1 | 2023 | 14 | 0.850 |
Why?
|
| Thiepins | 1 | 2019 | 5 | 0.700 |
Why?
|
| Mentors | 2 | 2017 | 660 | 0.690 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2023 | 1066 | 0.680 |
Why?
|
| Clinical Clerkship | 2 | 2023 | 564 | 0.680 |
Why?
|
| Education, Medical | 2 | 2022 | 1726 | 0.680 |
Why?
|
| Cluster Headache | 1 | 2020 | 54 | 0.670 |
Why?
|
| Models, Educational | 1 | 2022 | 373 | 0.650 |
Why?
|
| Goals | 2 | 2014 | 711 | 0.640 |
Why?
|
| Peanut Hypersensitivity | 1 | 2022 | 214 | 0.630 |
Why?
|
| Triazines | 1 | 2019 | 311 | 0.590 |
Why?
|
| Oxazines | 1 | 2019 | 348 | 0.580 |
Why?
|
| Curriculum | 5 | 2023 | 3732 | 0.570 |
Why?
|
| Quinoxalines | 1 | 2018 | 296 | 0.550 |
Why?
|
| Antiviral Agents | 2 | 2019 | 3066 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2015 | 12127 | 0.540 |
Why?
|
| Desensitization, Immunologic | 1 | 2022 | 541 | 0.530 |
Why?
|
| Advance Care Planning | 1 | 2023 | 694 | 0.500 |
Why?
|
| Physicians, Family | 2 | 2013 | 349 | 0.460 |
Why?
|
| Allergens | 1 | 2022 | 1410 | 0.460 |
Why?
|
| Physician-Patient Relations | 3 | 2023 | 3246 | 0.450 |
Why?
|
| Benzimidazoles | 1 | 2018 | 855 | 0.430 |
Why?
|
| Peer Group | 2 | 2017 | 684 | 0.400 |
Why?
|
| Burnout, Professional | 1 | 2021 | 704 | 0.400 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 771 | 0.390 |
Why?
|
| Teaching | 2 | 2022 | 1169 | 0.380 |
Why?
|
| Family Practice | 4 | 2022 | 509 | 0.370 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 1032 | 0.350 |
Why?
|
| Communication | 2 | 2014 | 3868 | 0.340 |
Why?
|
| Learning | 4 | 2023 | 1740 | 0.330 |
Why?
|
| Sulfonamides | 1 | 2018 | 1973 | 0.320 |
Why?
|
| Hypoglycemic Agents | 4 | 2014 | 3076 | 0.310 |
Why?
|
| Faculty, Medical | 1 | 2017 | 1202 | 0.310 |
Why?
|
| Influenza, Human | 1 | 2019 | 1517 | 0.310 |
Why?
|
| Morpholines | 2 | 2023 | 580 | 0.300 |
Why?
|
| Phenols | 1 | 2012 | 517 | 0.300 |
Why?
|
| Pyridines | 1 | 2019 | 2868 | 0.300 |
Why?
|
| Self Care | 1 | 2013 | 794 | 0.290 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 3702 | 0.290 |
Why?
|
| Migraine Disorders | 1 | 2020 | 1697 | 0.290 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 4518 | 0.280 |
Why?
|
| Pyridones | 2 | 2023 | 807 | 0.260 |
Why?
|
| HIV-1 | 1 | 2023 | 6859 | 0.250 |
Why?
|
| Physicians | 1 | 2021 | 4586 | 0.210 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 2318 | 0.210 |
Why?
|
| Internship and Residency | 2 | 2021 | 5866 | 0.210 |
Why?
|
| Powders | 1 | 2022 | 80 | 0.200 |
Why?
|
| Humans | 35 | 2024 | 760437 | 0.190 |
Why?
|
| Health Behavior | 1 | 2013 | 2637 | 0.190 |
Why?
|
| Metformin | 3 | 2014 | 905 | 0.190 |
Why?
|
| Hot Flashes | 1 | 2024 | 330 | 0.190 |
Why?
|
| Advance Directives | 1 | 2023 | 248 | 0.180 |
Why?
|
| Blood Glucose | 6 | 2015 | 6380 | 0.180 |
Why?
|
| Dibenzothiepins | 1 | 2019 | 8 | 0.180 |
Why?
|
| Drug Combinations | 2 | 2018 | 2043 | 0.170 |
Why?
|
| Lipids | 4 | 2014 | 3342 | 0.170 |
Why?
|
| Health Occupations | 1 | 2021 | 222 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 9176 | 0.170 |
Why?
|
| Aminoisobutyric Acids | 1 | 2018 | 39 | 0.160 |
Why?
|
| Schools, Medical | 2 | 2022 | 878 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2022 | 353 | 0.160 |
Why?
|
| Empathy | 1 | 2023 | 473 | 0.150 |
Why?
|
| Death | 1 | 2023 | 676 | 0.150 |
Why?
|
| Leucine | 1 | 2018 | 548 | 0.140 |
Why?
|
| Cyclopropanes | 1 | 2018 | 432 | 0.140 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 318 | 0.140 |
Why?
|
| Proline | 1 | 2018 | 457 | 0.140 |
Why?
|
| Pain | 1 | 2012 | 5075 | 0.140 |
Why?
|
| Pyrrolidines | 1 | 2018 | 338 | 0.140 |
Why?
|
| HIV Infections | 1 | 2023 | 17328 | 0.140 |
Why?
|
| Hypertension | 2 | 2013 | 8527 | 0.130 |
Why?
|
| Health Education | 1 | 2022 | 1052 | 0.130 |
Why?
|
| Menopause | 1 | 2024 | 1645 | 0.130 |
Why?
|
| Lipoproteins, LDL | 2 | 2016 | 642 | 0.120 |
Why?
|
| Career Mobility | 1 | 2017 | 258 | 0.120 |
Why?
|
| Counseling | 1 | 2022 | 1545 | 0.120 |
Why?
|
| Educational Status | 1 | 2022 | 2518 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2015 | 130 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2022 | 4010 | 0.110 |
Why?
|
| Injections | 1 | 2016 | 829 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 1781 | 0.110 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 242 | 0.100 |
Why?
|
| Smoking Cessation | 2 | 2014 | 2053 | 0.100 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 219 | 0.090 |
Why?
|
| Pandemics | 2 | 2021 | 8623 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 675 | 0.090 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 363 | 0.090 |
Why?
|
| Checklist | 1 | 2017 | 827 | 0.090 |
Why?
|
| Feedback | 1 | 2014 | 791 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 7380 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 461 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2014 | 635 | 0.080 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 397 | 0.080 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 311 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 2367 | 0.080 |
Why?
|
| Blood Pressure | 4 | 2013 | 8479 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2012 | 554 | 0.070 |
Why?
|
| Cost Savings | 1 | 2013 | 913 | 0.070 |
Why?
|
| Consensus | 1 | 2017 | 3115 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 2897 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12320 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 763 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2014 | 2493 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 3457 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2020 | 64591 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5704 | 0.060 |
Why?
|
| Adolescent | 2 | 2023 | 88196 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 2018 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 5815 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 6297 | 0.050 |
Why?
|
| Dermoscopy | 1 | 2023 | 66 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2013 | 2517 | 0.050 |
Why?
|
| Primary Health Care | 3 | 2023 | 4674 | 0.050 |
Why?
|
| United States | 4 | 2023 | 72202 | 0.050 |
Why?
|
| Life Style | 1 | 2013 | 3909 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2013 | 2166 | 0.050 |
Why?
|
| Dehydroepiandrosterone | 1 | 2001 | 258 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3685 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 29831 | 0.040 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 495 | 0.040 |
Why?
|
| Depression | 1 | 2019 | 8104 | 0.040 |
Why?
|
| Female | 6 | 2024 | 391875 | 0.040 |
Why?
|
| Lipoprotein(a) | 2 | 1994 | 480 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 42209 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 508 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3880 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2013 | 12932 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2012 | 4777 | 0.030 |
Why?
|
| Smoking | 1 | 2013 | 9046 | 0.030 |
Why?
|
| Career Choice | 1 | 2022 | 755 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4789 | 0.030 |
Why?
|
| Triglycerides | 2 | 2001 | 2458 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 4760 | 0.030 |
Why?
|
| Adult | 3 | 2023 | 220781 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 1994 | 95 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 835 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 1376 | 0.030 |
Why?
|
| Child | 1 | 2022 | 80086 | 0.030 |
Why?
|
| Quality of Life | 1 | 2014 | 13338 | 0.030 |
Why?
|
| Financial Support | 1 | 2012 | 117 | 0.020 |
Why?
|
| Body Composition | 1 | 2001 | 2421 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 12918 | 0.020 |
Why?
|
| Patient Participation | 1 | 2019 | 1442 | 0.020 |
Why?
|
| Middle Aged | 4 | 2022 | 220382 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4474 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 15476 | 0.020 |
Why?
|
| Male | 5 | 2022 | 360035 | 0.020 |
Why?
|
| Risk Factors | 2 | 2013 | 74055 | 0.020 |
Why?
|
| Drug Industry | 1 | 2012 | 788 | 0.020 |
Why?
|
| Exercise | 1 | 2001 | 5874 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 201 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1994 | 5919 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 1859 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 80430 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1993 | 299 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1993 | 386 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2001 | 22097 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1993 | 1178 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2001 | 3306 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1993 | 1814 | 0.000 |
Why?
|
| Reference Values | 1 | 1993 | 4921 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 14565 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1994 | 6340 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1993 | 6230 | 0.000 |
Why?
|
| Cholesterol | 1 | 1993 | 2902 | 0.000 |
Why?
|
| Family | 1 | 1993 | 3189 | 0.000 |
Why?
|
| Odds Ratio | 1 | 1994 | 9639 | 0.000 |
Why?
|
| Insulin | 1 | 1993 | 6591 | 0.000 |
Why?
|
| Phenotype | 1 | 1994 | 16585 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 36362 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1993 | 11453 | 0.000 |
Why?
|
Concepts
(174)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_